探讨尤瑞克林联合阿加曲班治疗急性脑梗死有效性及安全性

Clinical study on the efficacy and safety of human urinary kallidinogenase combined with argatroban in the treatment of acute cerebral infarctions

目的探讨尤瑞克林联合阿加曲班治疗急性脑梗死的有效性及安全性。方法选择急性脑梗死患者160例,随机分为治疗组和对照组,每组80例。治疗组给予尤瑞克林联合阿加曲班治疗,对照组仅给予阿加曲班治疗。分别观察两组患者治疗前、后7、14、30、90 d神经功能缺损评分(NIHSS评分),Barthel指数,疗效及不良反应情况。结果治疗后7、14、30、90 d,治疗组NIHSS评分低于对照组,Barthel指数高于对照组,组间比较,差异均有统计学意义(P<0.01);治疗组总有效率明显高于对照组,差异有统计学意义(P<0.05)。两组患者在治疗过程中未发生严重不良反应。结论尤瑞克林联合阿加曲班治疗急性脑梗死患者,能够明显改善患者的神经功能缺损症状,疗效好,安全性高。

Objective To explore the clinical efficacy and safety of human urinary kallidinogenase combined with argatroban in the treatment of acute cerebral infarctions. Methods Totally 160 patients with acute cerebral infarction were randomly divided into the observation group（n=80）and the control group（n=80）. Patients were treated with urinary kallidinogenase combined with argatroban in the observation group. Patients were just treated with argatroban in the control group. The degree of neurological deficit was com-pared using the national institutes of health stroke scale（ NIHSS） scoring and the rehabilitation condition was evaluated by Barthal in-dex（ BI） between two groups before treatment and 7 days,14 days,30 days and 90 days after treatment,respectively. The clinical effects were masured,and the adverse reactions were observed. Results NIHSS scores at 7th day,14th day,30th day and 90th day were low-er than those in the control group,the BI was higher than that in the control group,the difference between two groups had statistical sig-nificance（ P〈0. 01 ） . The total effective rate of the observation group was significantly higher than that of the control group （ P 〈0. 05）. There was no serious adverse reaction occurred during treatment. Conclusion Patients with acute infarction that are treated with human urinary kallidinogenase combined with argatroban is significantly improved in the neurologic impairment compares with the control group,the clinical effects are better,and more security.